Myovant Sciences receives positive CHMP opinion for Ryeqo (relugolix combination tablet) for the treatment of women with uterine fibroids
Myovant Sciences announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending the approval of Ryeqo (relugolix… read more.
